2025-07-30 東京大学,京都大学,ステラファーマ株式会社
開発したポリビニルアルコール製剤による悪性胸膜中皮腫モデルの治療
<関連情報>
- https://www.c.u-tokyo.ac.jp/info/news/topics/20250730050000.html
- https://www.sciencedirect.com/science/article/pii/S0378517325007926?via%3Dihub
ポリビニルアルコールは、中性子捕獲療法における胸腔腫瘍に対する4-L-ボロフェニルアラニンの治療効果を強化する Poly(vinyl alcohol) enhancing therapeutic effects of 4-l-boronophenylalanine on thoracic tumors in neutron capture therapy
Kakeru Konarita, Minoru Suzuki, Daiki Tokura, Megumi Sunahara, Aya Sudani, Yuko Ishino, Hideki Nakashima, Toshimitsu Hayashi, Koki Uehara, Nobuhiro Nishiyama, Takahiro Nomoto
International Journal of Pharmaceutics Available online: 29 July 2025
DOI:https://doi.org/10.1016/j.ijpharm.2025.125955
Abstract
Boron neutron capture therapy (BNCT) has been expected to be a promising approach to treat lung cancers in a non-invasive manner. Development of boron drugs showing efficient accumulation and long-term retention within the target tumor is key to realizing BNCT for such deep-seated cancers. Here, we report that the complex comprising poly(vinyl alcohol) (PVA) and 4-l-boronophenylalanine (BPA), the only clinically approved drug in BNCT, could show drastic therapeutic efficiency to thoracic tumors mimicking intractable malignant pleural mesothelioma (MPM) in mice. We first optimized the preparation method and composition of the formulation with the aid of sorbitol as a solubilizer. The optimized formulation termed PVA-sorbitol-BPA exhibited dramatical reduction of possible side effects to ignorable levels in comparison with the prototype of PVA-BPA complexes. Systemically administered PVA-sorbitol-BPA showed efficient accumulation and long-term retention within the target tumor. BNCT with PVA-sorbitol-BPA significantly improved survival rates even compared with conventional BPA. Our results indicate that PVA may be a promising additive to boost the therapeutic potential of BPA for treatment of tumors in the torso, expanding the indications for BNCT.
